Press Releases from Trovagene, Inc. (6 total)
Trovagene Cited Among Top Molecular Diagnostic Developers
SAN DIEGO – Trovagene, Inc., a developer of transrenal molecular diagnostics, was placed in lofty company with Abbott Diagnostics and Rosetta Genomics in the increasingly important molecular diagnostics sector.
Mel Daris, a former mutual fund industry trader from Boston who currently trades independently, singled out the three companies in a Seeking Alpha report on the medical community’s expanding interest in molecular diagnostic testing.
“With advances in testing procedures, especially transrenal DNA…
Trovagene Called Well-Placed in Global Molecular Diagnostic Industry by NASDAQ
NEW YORK – Fresh from a successful public offering and new listing on the NASDAQ stock exchange, Trovagene CEO Antonius Schuh was given the honor of ringing the closing bell at Nasdaq’s Times Square marketsite. Standing in front of his management team, board of directors and special guests, Schuh reviewed Trovagene’s progress in developing faster, more accurate and less invasive diagnostics through urine analysis.
"Now we can watch how a cell…
Novel Urine Tests for Cancer Under Development to Replace Blood Samples
SAN DIEGO -- Scientists at Trovagene, Inc. (Pink Sheets: TROV.PK), a developer of trans-renal molecular diagnostics, are working to develop novel tests to detect tumor-derived DNA in cancer patients through a patient's urine, rather than blood samples.
"By the end of the year, we hope to introduce a novel k-RAS gene test that detects mutations in pancreatic and colon cancers," said Antonius Schuh, Trovagene's Chief Executive…
TrovaGene Expands Franchise of Proprietary Markers in Hematological Cancers With …
SAN DIEGO -- TrovaGene, Inc. (Pink Sheets: TROV), a developer of trans-renal molecular diagnostics, announced it has obtained an exclusive worldwide license to mutations of the SF3B1 splicing factor, which have been shown to be associated with disease progression and chemotherapy response in patients suffering from chronic lymphocytic leukemia (CLL).
The findings have been published in the Dec 22 issue of BLOOD, the journal of the American Society of Hematology, in…
Antonius Schuh Named CEO of TrovaGene, Inc. and Sets Sights on Novel Diagnostics …
SAN DIEGO -- TrovaGene, Inc. (Pink Sheets: TROV.PK), a developer of trans-renal molecular diagnostics, has announced that Antonius Schuh, Ph.D. has been named Chief Executive Officer.
Dr. Schuh previously served as Chairman and Chief Executive Officer of Sorrento Therapeutics, Inc. (Pink Sheets: SRNE.PK), a biotechnology company he co-founded based on a proprietary platform to generate very large fully human antibody libraries. Sorrento Therapeutics merged in 2009 with a public…
Aiming to Develop Novel Cervical Cancer Screening Test
SAN DIEGO, CA – TrovaGene, Inc., is preparing to launch clinical studies aimed at developing the first non-invasive, urine-based screening test for the human papilloma virus (HPV) that causes cervical cancer, a top officer of the molecular diagnostics products company announced today.
“We expect the studies to commence in the first quarter of next year,” said Kerry Segal, TrovaGene’s Chief Business Officer.
"The studies will…
